A Pilot Phase II Study of Selinexor in Combination With Induction/Consolidation/Maintenance Therapy in Older AML Patients
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Selinexor (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 09 Feb 2018 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.
- 09 Feb 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
- 09 Feb 2018 Status changed from suspended to recruiting.